Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

PC111Positive

AI Analysis

Summary

Scinai Immunotherapeutics executed a second amendment to its binding option agreement for PinCell S.r.l. acquisition and submitted a revised €12 million non-dilutive FENG application to advance the PC111 program through human proof of concept.

Clinical Trial Data

Phase

Proof of Concept

Outcome Details

Second Amendment to PinCell Option Agreement executed; revised €12 million non-dilutive FENG application submitted to advance PC111 through human proof of concept

Importance:6/10

Sentiment:

0.50

acquisitionoption agreementfundingnon-dilutiveimmunotherapyproof of concept

Related Companies

$SCNI

Read the original article

Published by PR Newswire Biotech on March 2, 2026 2:20 PM

Read Original